OncLive® On Air cover image

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

OncLive® On Air

00:00

Epcot-Nhl1: A Comprehensive Cancer Treatment

An overall response rate of 63%, which is pretty good, but obviously that's not necessarily the biggest indicator of response in diffuse large B-SIL lymphoma. For patients who get a complete remission, it does appear that those patients are having a durable response. The drug is given up at a step up dose in fashion to reduce some of the side effects that we talked about, such as CRS and ICANN's.

Play episode from 04:30
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app